Otilonium BromideCAS# 26095-59-0 |
- AM630
Catalog No.:BCC1353
CAS No.:164178-33-0
- Nepicastat
Catalog No.:BCC1795
CAS No.:173997-05-2
- JWH 073
Catalog No.:BCC1674
CAS No.:208987-48-8
- CP-945598 HCl
Catalog No.:BCC1082
CAS No.:686347-12-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 26095-59-0 | SDF | Download SDF |
| PubChem ID | 72092 | Appearance | Powder |
| Formula | C29H43BrN2O4 | M.Wt | 563.57 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Octylonium bromide; SP63 | ||
| Solubility | H2O : ≥ 100 mg/mL (177.44 mM) DMSO : 50 mg/mL (88.72 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide | ||
| SMILES | [Br-].CCCCCCCCOc1ccccc1C(=O)Nc2ccc(cc2)C(=O)OCC[N+](C)(CC)CC | ||
| Standard InChIKey | VWZPIJGXYWHBOW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C29H42N2O4.BrH/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3;/h12-13,15-20H,5-11,14,21-23H2,1-4H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Otilonium Bromide is an antimuscarinic used as a spasmolytic agent.
Target: mAChR
Otilonium bromide inhibited the generation of ACh-induced calcium signals in a dose dependent manner (IC50=880 nM) [1]. Otilonium, a clinically useful spasmolytic, behaves as a potent blocker of neuronal nicotinic acetylcholine receptors (AChR). Whole-cell Ba2+ currents (IBa) through Ca2+ channels of voltage-clamped chromaffin cells were blocked by otilonium with an IC50 of 6.4 microM. Otilonium inhibited the secretory responses induced by 10 s pulses of 50 microM DMPP with an IC50 of 7.4 nM [2]. Otilonium bromide may represent an effective treatment for irritable bowel syndrome because it reduces its predominant symptom (abdominal pain/ discomfort) more than placebo does [3]. ilonium bromide (OB) is a spasmolytic agent that blocks L-Type Calcium channels in human colonic smooth muscle. otilonium bromide is safe, well tolerated and superior to placebo in reducing the frequency of abdominal pain, severity of abdominal bloating and protecting from symptom relapse in IBS. These results further confirm that patients with IBS can improve during and following treatment with otilonium bromide [4]. References: | |||||
Otilonium Bromide Dilution Calculator
Otilonium Bromide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7744 mL | 8.872 mL | 17.744 mL | 35.488 mL | 44.3601 mL |
| 5 mM | 0.3549 mL | 1.7744 mL | 3.5488 mL | 7.0976 mL | 8.872 mL |
| 10 mM | 0.1774 mL | 0.8872 mL | 1.7744 mL | 3.5488 mL | 4.436 mL |
| 50 mM | 0.0355 mL | 0.1774 mL | 0.3549 mL | 0.7098 mL | 0.8872 mL |
| 100 mM | 0.0177 mL | 0.0887 mL | 0.1774 mL | 0.3549 mL | 0.4436 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Otilonium bromide is an antimuscarinic.
- AMC
Catalog No.:BCC2837
CAS No.:26093-31-2
- Byakangelicol
Catalog No.:BCN5015
CAS No.:26091-79-2
- (-)-Oxypeucedanin
Catalog No.:BCC9244
CAS No.:26091-73-6
- Myrciaphenone A
Catalog No.:BCN7003
CAS No.:26089-54-3
- Sotetsuflavone
Catalog No.:BCN3846
CAS No.:2608-21-1
- 3-Isomangostin hydrate
Catalog No.:BCN5134
CAS No.:26063-96-7
- 1-Isomangostin hydrate
Catalog No.:BCN5133
CAS No.:26063-95-6
- Boc-Asp(OBzl)-ONp
Catalog No.:BCC3364
CAS No.:26048-69-1
- Beauvericin
Catalog No.:BCC6546
CAS No.:26048-05-5
- PD173955
Catalog No.:BCC3999
CAS No.:260415-63-2
- Ligustroflavone
Catalog No.:BCN2370
CAS No.:260413-62-5
- Dihydroisotanshinone II
Catalog No.:BCN5132
CAS No.:260397-58-8
- Reneilmol
Catalog No.:BCN5135
CAS No.:260968-11-4
- Chicago Sky Blue 6B
Catalog No.:BCC6816
CAS No.:2610-05-1
- Cyanidin-3,5-O-diglucoside chloride
Catalog No.:BCN3116
CAS No.:2611-67-8
- Rhodojaponin II
Catalog No.:BCN2810
CAS No.:26116-89-2
- Picrasin B
Catalog No.:BCN5136
CAS No.:26121-56-2
- Madurensine
Catalog No.:BCN2092
CAS No.:26126-78-3
- 4-O-Feruloylquinic acid
Catalog No.:BCN3352
CAS No.:2613-86-7
- Frentizole
Catalog No.:BCC4035
CAS No.:26130-02-9
- Antiarol rutinoside
Catalog No.:BCN5137
CAS No.:261351-23-9
- MB05032
Catalog No.:BCC1731
CAS No.:261365-11-1
- Linderene
Catalog No.:BCN2779
CAS No.:26146-27-0
- Linderene acetate
Catalog No.:BCN8042
CAS No.:26146-28-1
Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.[Pubmed:25930994]
Neurogastroenterol Motil. 2015 Jul;27(7):997-1009.
BACKGROUND: Otilonium Bromide (OB) is used as a spasmolytic drug in the treatment of the functional bowel disorder irritable bowel syndrome. Although its acute effects on colonic relaxation are well-characterized, little is known about the effects of chronic administration of OB on enteric neurons, neuromuscular transmission, and interstitial cells of Cajal (ICC), key regulators of the gut function. METHODS: Adult Sprague-Dawley rats were treated with OB in drinking water at a dose of 2 mg/kg for 30 days. The colons of OB-treated and age-matched control rats were studied by confocal immunohistochemistry to detect immunoreactivity (IR) in myenteric plexus neurons for nitrergic and tachykininergic markers, and also by microelectrode electrophysiology. KEY RESULTS: Using immunohistochemistry, chronic OB administration did not change total neuron number, assessed by anti-Hu IR, but resulted in a significant increase in NK1 receptor positive neurons, a decrease in neuronal nitric oxide synthase expressing neurons, and a reduction in volume of substance P in nerve fibers in the myenteric plexus. Chronic OB administration potentiated inhibitory and excitatory junction potentials evoked by repetitive electrical field stimulation. The various types of colonic ICC, detected by Kit IR, were not altered nor were slow waves or smooth muscle membrane potential. CONCLUSIONS & INFERENCES: Chronic treatment with OB caused significant changes in the nitrergic and tachykinergic components of the myenteric plexus and in both inhibitory and excitatory neurotransmission in the rat colon.
Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.[Pubmed:28246548]
Therap Adv Gastroenterol. 2017 Mar;10(3):311-322.
BACKGROUND: Otilonium Bromide (OB) is a spasmolytic agent acting as an L-type calcium channel antagonist in intestinal and colonic smooth muscle cells (SMCs). We analyzed three independent clinical trials with homogeneous design on patients with irritable bowel syndrome (IBS). After 2 weeks receiving placebo, patients were randomized to receive OB (3 x 40 mg daily) or placebo for 15 weeks. We aimed to perform a pooled analysis of the data from these homogeneous clinical trials to evaluate the efficacy of OB treatment on symptoms and global response of patients. METHODS: A total of 883 patients with IBS (69.8% women, mean age 46.2 years, 43.8% mixed type) were included, 442 treated with OB and 441 with placebo. The efficacy results from the three studies at weeks 5, 10 and 15 were pooled in an intention-to-treat (ITT) strategy, analyzed with a logistic regression model and described by forest plots. RESULTS: Despite a placebo effect in all efficacy variables, a significant therapeutic effect of OB was observed at weeks 10 and 15 with reference to: (a) intensity and frequency of abdominal pain; (b) rate of responders as evaluated by patients (71.8% at week 10 and 77.2% at week 15); (c) severity of bloating; (d) rate of responders as evaluated by physicians (55% at week 10 and 63.9% at week 15). No significant OB effect was observed in stool frequency and consistency. CONCLUSIONS: OB is more effective than placebo in IBS treatment. Therapeutic benefits are significant after 10 weeks and are maximal after 15 weeks of treatment.
Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.[Pubmed:27866394]
J Cell Mol Med. 2017 Apr;21(4):735-745.
Otilonium Bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS). Its efficacy has been attributed to the block of L- and T-type Ca(2+) channels and muscarinic and tachykinin receptors in the smooth muscle. Furthermore, in healthy rats, repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action. On this basis, we investigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms. In control, WRS and OB/WRS rats functional parameters were measured in vivo and morphological investigations were done ex vivo in the colon. The results showed that OB counteracts most of the neurotransmitters changes caused by WRS. In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100beta-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR. On the contrary, OB does not affect the increase in CRF2r-IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS. Finally, OB per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons. Functional findings show a significantly reduction in the number of spontaneous abdominal contraction in OB treated rats. The ability of OB to block L-type Ca(2+) channels, also expressed by enteric neurons, might represent a possible mechanism through which OB exerts its actions.
A New, More Stable Polymorphic Form of Otilonium Bromide: Solubility, Crystal Structure, and Phase Transformation.[Pubmed:27444388]
J Pharm Sci. 2016 Oct;105(10):3013-3020.
A new polymorphic form of Otilonium Bromide is presented (Form I), and a thorough analysis of its crystal and molecular structure is performed. The compound suffers a temperature-driven first-order phase transition at about 396 K, which transforms it into the polymorph reported by Dapporto P and Sega A (Acta Cryst. 1986;C42:474-478) (Form II). Through thermal analysis and solubility experiments the relative stability of both crystal modifications were determined, confirming that at room temperature this new Form I is the more stable one, Form II existing just in a metastable state.
